Immunome, Inc. $IMNM Shares Acquired by Sei Investments Co.

Sei Investments Co. lifted its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 90.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,770 shares of the company’s stock after purchasing an additional 25,051 shares during the quarter. Sei Investments Co.’s holdings in Immunome were worth $1,154,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Nan Fung Trinity HK Ltd. increased its stake in Immunome by 20.7% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after buying an additional 122,450 shares during the period. Vanguard Group Inc. lifted its stake in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares during the period. Profund Advisors LLC lifted its stake in shares of Immunome by 121.7% in the 4th quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock worth $917,000 after acquiring an additional 23,440 shares during the period. Maven Securities LTD purchased a new stake in shares of Immunome in the fourth quarter valued at about $1,611,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Immunome in the fourth quarter valued at about $3,652,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the sale, the insider owned 15,805 shares of the company’s stock, valued at $357,509.10. The trade was a 77.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 15,248 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $26.06, for a total value of $397,362.88. Following the completion of the sale, the director owned 72,416 shares in the company, valued at approximately $1,887,160.96. This represents a 17.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 598,846 shares of company stock worth $13,476,656. Company insiders own 7.21% of the company’s stock.

Analyst Ratings Changes

IMNM has been the topic of a number of recent analyst reports. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Citigroup reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Leerink Partners reduced their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.18.

Immunome Stock Up 2.2%

Shares of NASDAQ IMNM opened at $26.25 on Wednesday. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -11.03 and a beta of 2.08. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $27.65. The firm has a 50-day moving average price of $21.73 and a 200 day moving average price of $22.18.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities research analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.